Pneumonia, most often caused by a respiratory virus, is common in childhood. Mycoplasma pneumoniae also is detected frequently, particularly in older children in the era of pneumococcal conjugate vaccination. Despite recommendations for β-lactam antibiotics, macrolide antibiotics, including erythromycin, clarithromycin, and azithromycin, are prescribed frequently to children with acute lower respiratory infection. However, the significance of detecting "atypical" pathogens, including M pneumoniae, in children remains contentious. Considering the potential for antibacterial and anti-inflammatory activities of macrolides, our understanding of the role of these drugs in acute and chronic infections and in inflammatory conditions is changing. Some observational data have revealed improved outcomes in adults and children with pneumonia who are prescribed macrolides, although its widespread use has led to increases in macrolide resistance in Streptococcus pneumoniae and M pneumoniae. Clinical trials to define the role of macrolides in pediatric acute respiratory infection must be prioritized.
Pneumonia is one of the leading causes of hospitalization for children in the United States and results in a significant burden to children, families, and the healthcare system [1] . Current Infectious Diseases Society of America guidelines for children and adolescents with community-acquired pneumonia (CAP) recommend amoxicillin for mild-to-moderate CAP and ampicillin or benzyl-penicillin for children with more severe disease [2] . In addition, consideration for withholding antimicrobial therapy for young children with mild disease is recommended given the burden of respiratory viruses in this age group. Macrolide antibiotics are recommended for children with findings compatible with CAP secondary to atypical pathogens (eg, Mycoplasma pneumoniae) or in the setting of severe β-lactam allergy. British guidelines state that macrolide antibiotics can be added to amoxicillin if there is no response to first-line therapy, if atypical pathogens are considered likely, or if disease is very severe [3] . Despite this relatively narrow recommendation for macrolide antibiotics, they continue to be prescribed to 35% to 42% of children with CAP [4, 5] .
Recent studies in which the etiology of CAP in the setting of high pneumococcal conjugate vaccine (PCV) coverage was explored found frequent detection of respiratory viruses and M pneumoniae in children [6] . A lack of rapid and reliable tests for bacterial pneumonia in children and the nonspecific clinical features of atypical pneumonia leave clinicians uncertain about the likely etiology at the point of antibiotic prescription. Conflicting data about the true role of M pneumoniae in pediatric CAP [7] , increasing macrolide resistance in both Streptococcus pneumoniae and M pneumoniae, and observational data on improved outcomes in those with CAP who are prescribed non-β-lactam antibiotics make empiric antibiotic choices for children with CAP an area of ongoing controversy. Given this background, it is time to reconsider the 6-year-old recommended options for children with CAP [2, 3] . In this review, we focus particularly on the role of macrolide antibiotics.
ETIOLOGY OF CAP IN CHILDHOOD
The recent Centers for Disease Control and Prevention-funded Etiology of Pneumonia in the Community (EPIC) study sought to determine the viral and bacterial etiologies of radiologically confirmed CAP in hospitalized children in the United States between January 2010 and June 2012 [6] . It should be noted that this study occurred nearly 1 decade after the introduction of PCVs and concurrent with the shift from the 7-valent to the 13-valent PCV; therefore, generalizing these results to other settings, particularly those with higher rates of pneumococcal colonization or lower PCV coverage, should be done cautiously. In the EPIC study, bacterial pathogens, including S pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Staphylococcus aureus, were identified by blood culture, wholeblood polymerase chain reaction (PCR) assays (for S pneumoniae and S pyogenes only), and, when available, pleural fluid culture and PCR assays. The same pathogens were identified from endotracheal aspirates and bronchoalveolar lavage fluid samples (culture only), when such samples were available. M pneumoniae and Chlamydophila pneumoniae were detected by using PCR assays on nasopharyngeal (NP) and oropharyngeal (OP) swabs. Viral pathogens were detected by PCR on NP and OP swabs and by acute-and convalescent-phase serology testing [6] . Healthy asymptomatic child controls were recruited between February 2011 and June 2012. A pathogen was detected in 81% of these children, which is significantly more than the 38% observed in a concurrently conducted study in adults [8] . Respiratory viruses, including respiratory syncytial virus (RSV), human rhinovirus, and human metapneumovirus, were the most frequently identified pathogen in all pediatric age groups. Of the bacterial pathogens identified, M pneumoniae was the most frequently detected (8% of patients, ranging from 2% of those aged <2 years to 23% of those aged 10 years or older); this pathogen was detected significantly more often than was pneumococcus (4%) and S aureus (1%) [6] . Other intracellular pathogens, including C pneumoniae, were detected infrequently in all age groups (<1%). Apart from human rhinovirus, other viral and bacterial pathogens (including M pneumoniae) were identified infrequently from NP/OP swabs of asymptomatic control children.
The more frequent detection of M pneumoniae in patients than in controls in the EPIC study lies in contrast to that in a recently published Dutch case-control study undertaken during a period of increased M pneumoniae activity in Europe. Using PCR and mycoplasma culture, Spuesens et al [7] identified similar rates of M pneumoniae detection and load in both populations (16% in children with acute respiratory infection and 21% in asymptomatic children). These results confirm the possibility of detection (or carriage) of M pneumoniae in asymptomatic children, particularly during periods of increased M pneumoniae activity, and they raise questions about the significance of M pneumoniae detection in children with and in those without pneumonia.
Despite the advancements in rapid diagnostics, many of which were used in the aforementioned studies, there remains an ongoing lack of sensitive and specific diagnostics for pediatric CAP. Diagnostic testing is performed frequently on upper respiratory tract samples; because pneumonia is a disease of the lower airways, this approach, although most practical, might not reflect the true bacterial etiology of pneumonia (which, for example, could account for the relatively low rate of identification of pneumococcus in the EPIC study). The lack of sensitive and specific diagnostics is compounded further by our inability to reliably and clinically distinguish CAP caused by different pathogens; in a meta-analysis of prospective cohort studies in which children with CAP were examined, clinical features that distinguished those with from those without M pneumoniae-associated CAP included chest pain and crepitations (more frequent in those with Mycoplasma infection) and wheeze (less frequent in those with Mycoplasma infection), yet no features were sufficiently reliable to distinguish Mycoplasma-associated CAP on the basis of clinical signs [9] . This inherent limitation leads to empiric antibiotic use for pediatric CAP.
MACROLIDES:
ANTIBACTERIAL ACTION AND RESISTANCE
The macrolide class of antibiotics, derived from natural compounds produced by Gram-positive Streptomyces species, are characterized by a 14-membered (erythromycin, roxithromycin, clarithromycin), 15-membered (azithromycin), or 16-membered (josamycin, spiramycin) lactone ring to which amino and neutral side sugars are attached. As a class, macrolides are characterized by moderately broad-spectrum activity that includes most Gram-positive bacteria, some Gram-negative bacteria, and several bacteria responsible for intracellular infection (eg, Mycoplasma spp, Chlamydia spp, Legionella spp, and numerous Mycobacterium spp) [10] . The bacteriostatic properties of macrolides are attributable to reversible binding to the 23S ribosomal RNA (rRNA) of the 50S bacterial ribosomal subunit, which thereby inhibits RNAdependent protein synthesis.
A rise in macrolide resistance in respiratory pathogens, including in both S pneumoniae and M pneumoniae, has been reported globally. Resistance to macrolide antibiotics most frequently occurs as a result modification of the ribosomal target by methylation or mutation, decreased uptake of the molecules, and/or active efflux of the drug [11] . In pneumococci, methylation of the 23S rRNA (most frequently attributable to a family of rRNA methyltransferases designated Erm enzymes) and drug efflux (most frequently attributable to msrA gene-encoded ABC transporter and mefA gene-encoded MFS [major facilitator superfamily] pumps) are the most frequent causes of resistance [11] . In M pneumoniae, a number of specific point mutations in the 23s rRNA gene that affect attachment of the macrolide molecule and various degrees of drug resistance have been described [12, 13] . Rates of macrolide resistance in pneumococcus vary greatly among those in different countries [14] . Contemporary data from US children (2012-2014) suggest that half of pneumococci are macrolide resistant, but <10% are resistant to penicillin [15] . Macrolide-resistant M pneumoniae has also emerged more recently with resistance rates that range from <10% in the United States [16] and United Kingdom [17] to >90% in some Asian countries [12] . The rates of resistance in both S pneumoniae and M pneumoniae closely parallel community antimicrobial use, particularly in children [16] [17] [18] . Recently, solithromycin, a next-generation fluoroketolide macrolide that retains activity against most macrolide-resistant strains, was developed. Safety and efficacy trials in pediatric patients with CAP are underway (ClinicalTrials.gov identifier NCT02605122).
MACROLIDES: IMMUNOMODULATORY AND ADDITIONAL ANTIBACTERIAL AND ANTIVIRAL EFFECTS
In ecological studies, patients prescribed erythromycin for diffuse pan-bronchiolitis, an inflammatory disorder that is characterized by progressive neutrophil-associated suppurative and obstructive airway disease with progression to bronchiectasis and was first noted in east-Asian adults [19] [20] [21] , had a significantly improved survival rate and experienced improvement in their symptoms and radiological features. Similar effects have been found with other 14-and 15-member macrolides [22] [23] [24] . Findings of the immunomodulatory effect of macrolides, in addition to any direct antibacterial effect, have led to their use for a number of other inflammatory and infective conditions.
Several randomized placebo-controlled clinical trials of macrolides in children and adults with chronic inflammatory or infectious conditions have been conducted. A meta-analysis of clinical trials found improvement in forced expiratory volume over 1 second (FEV 1 ) (mean difference in FEV 1 , 4.0% [95% confidence interval (CI), 1.7; 6.1%]) and an increase in the odds of being free of pulmonary exacerbations after 6 months in selected subjects with cystic fibrosis (CF) who were given azithromycin compared with those who were given placebo [25] . In a recently published report from a placebo-controlled clinical trial in non-CF-associated bronchiectasis, a reduction in pulmonary exacerbations over a 6-month period was found in subjects prescribed azithromycin, despite the failure to detect a difference in symptom scores or FEV 1 s [26] . In adults after lung transplantation, bronchiolitis obliterans-free survival was found in those given prophylactic azithromycin compared with those given placebo (hazard ratio, 0.27 [95% CI, 0.09-0.82 ]) [27] . In a clinical trial in adults with chronic obstructive pulmonary disease, the median time to first exacerbation was 92 days longer in subjects prescribed long-term azithromycin than in those given placebo (P < .001) [28] . Variations in the macrolide used, doses, and frequency of administration have made generalizability of the findings from clinical trials difficult to implement in everyday clinical practice.
There has been significant interest in the role of macrolides in preventing acute exacerbations of chronic asthma. A recent meta-analysis of 23 clinical trials that compared children and adults prescribed prolonged macrolide therapy or placebo failed to find any difference in exacerbations, other treatments, symptoms, or quality of life [29] . Investigators have also examined the role of macrolides in the treatment of acute exacerbations of asthma. As reported by Johnston et al [30] , a 10-day course of telithromycin, a structurally similar ketolide antibiotic, when prescribed within 24 hours of a medically attended acute asthma exacerbation in adults aged 18 to 55 years with a history of asthma, resulted in a small but significant reduction in symptom scores compared with those who were given placebo (no difference in FEV 1 values was detected). More recently, children aged 1 to 3 years with recurrent asthma-like symptoms were allocated randomly to receive either 3 days of azithromycin or placebo in a blinded fashion during an acute episode (at least 3 days of cough, wheeze, or dyspnea) [31] . Of 158 randomized episodes, therapy for 154 episodes was completed. In the 148 episodes with adequate follow-up, a significant reduction in the number of symptomatic days was noted (3.4 vs 7.7 days [azithromycin vs placebo, respectively]; 63.3% reduction with azithromycin [95% CI, 56.0; 69.3%]). No effect on the time to next exacerbation was identified. The authors of both trials acknowledged that undiagnosed bacterial infection or macrolide-associated immunomodulatory effects could have resulted in the outcomes observed.
The mechanism by which macrolides exert their immunomodulatory action are complex, and an in depth description is beyond the scope of this review [32, 33] . In brief, macrolides exert their effect through (1) reducing neutrophil accumulation in the airway epithelium, which results in a reduction in local production of interleukin 8 (IL-8), (2) reducing the production of proinflammatory IL-1β and tumor necrosis factor α (TNF-α) in macrophages, which results in a further reduction in proinflammatory cytokines (IL-6 and IL-12) and increased anti-inflammatory cytokine production (IL-10), (3) downregulating production of proinflammatory mediators (prostaglandin E2, nitric oxide, TNF-α, IL-8, and IL-1a), (4) modulating key transcription factors, such as activator protein 1 (AP-1) and nuclear factor κB (NFκB), and (5) decreasing airway mucus production.
As found in cell-culture studies, certain macrolides also can influence acute viral infection by downregulating antiviral receptors and inhibiting virus production; the production of intercellular admission molecule 1 (ICAM-1), the receptor for entry by human rhinoviruses, and activated RhoA, a receptor for respiratory syncytial virus F protein, is downregulated by macrolides [34, 35] , and late-stage influenza A virus production also seems to be blocked by macrolides [36] . Additional antibacterial effects have been found at subtherapeutic macrolide concentrations, particularly in in vitro models with Pseudomonas aeruginosa; downregulation of virulence factor production, motility, and biofilm formation have all been found [37, 38] . It is highly possible that these additional actions influence outcomes in acute and chronic respiratory conditions.
ADULT PNEUMONIA: EVIDENCE SUPPORTING MACROLIDE USE
Current Infectious Diseases Society of America guidelines [39] (published in 2007) recommend combination β-lactam-macrolide therapy or respiratory fluoroquinolone monotherapy for adults with CAP who have an underlying comorbidity, are at increased risk of drug-resistant S pneumoniae (DRSP) infection, or require hospitalization (regardless of comorbidities or DRSP risk). In previously healthy adults with outpatient CAP (CAP not requiring hospitalization), macrolide or doxycycline monotherapy is recommended.
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Numerous analyses have explored the role of macrolides in adults with pneumonia, and conflicting results have been found. After pooling outcomes from clinical trials that enrolled adults hospitalized with CAP, Eliakim-Raz et al [40] failed to find any advantage of giving empiric coverage (including macrolides) for atypical organisms. In their study of adults with acute lower respiratory infection (including acute bronchitis, acute exacerbations of chronic bronchitis, and pneumonia) enrolled in clinical trials, Laopaiboon et al [41] also did not identify any difference in outcomes when azithromycin was compared with β-lactam therapy. These results are in contrast to those from observational studies; Asadi et al [42] found a significant reduction in the mortality rate in adults hospitalized with CAP who were prescribed macrolides compared with those who were not prescribed macrolides (relative risk [RR] , 0.78 [95% CI, 0.64-0.95]; P = .01; n = 137 574). This effect disappeared, however, when the analysis was restricted to data from clinical trials (RR, 1.13 [95% CI, 0.65-1.98]; P = .66; n = 1092). Superior outcomes for combined β-lactam and macrolide therapy were also found in a pooled analysis of cohort studies (odds ratio [OR], 0.67 [95% CI, 0.61-0.73]; P < .001; n = 42 942) [43] .
CHILDHOOD PNEUMONIA: EVIDENCE SUPPORTING MACROLIDE USE
Despite their frequent prescription for children, there remains a paucity of pediatric data from specific examinations of the role of empiric and targeted macrolide therapy for CAP. Published data from clinical trials and observational studies in which the efficacy of macrolide therapy was assessed in comparison with that of the standard of care are listed in Table 1 . Apart from a small single-center trial that found more rapid improvement in radiological findings in physician-defined "classic" pneumonia and more rapid improvement in symptoms in physician-defined atypical pneumonia [44] , clinical trials have yet to show any advantage of prescribing macrolides, either alone or in combination, over β-lactams in younger children. None of the studies recruited sufficient numbers of older children or compared β-lactams and macrolides in the groups. Observational studies, with the attendant difficulties in adjusting for differences in prescribing between patient groups, have explored the impact of macrolide use. Ambroggio et al [56] compared 1164 children with CAP who were managed in an outpatient setting and prescribed β-lactam monotherapy with the same number of children who were prescribed macrolide monotherapy. No difference in treatment failure (hospitalization or re-presentation requiring a change of drug within 14 days) was observed in children aged ≤5 years (adjusted OR [aOR], 0.90 [95% CI, 0.37-2.22]), but a trend toward better outcomes was seen in children aged >5 years (aOR, 0.48 [95% CI, 0.22-1.01]). The report from another study performed by the same authors, a large multicenter retrospective cohort study of children hospitalized with CAP, described outcomes for children given combination β-lactam-macrolide therapy compared with those for children prescribed β-lactam monotherapy. A 20% reduction in length of stay was observed in those prescribed combination therapy, and the effect size was greatest in older children (Table 1) .
A lack of trial data supporting treatment recommendations that specifically consider the role of macrolide therapy in children with proven atypical pneumonia also remains [45] . Evidence that supports treatment recommendations are derived from observational data; Principi et al [46] described 210 and 87 children aged 2 to 14 years with laboratory-confirmed (according to results from serology and/or PCR testing of respiratory specimens) M pneumoniae or Chlamydia pneumoniae infection, respectively, the majority of whom had radiologically confirmed pneumonia. Of the 191 children with M pneumoniae and/or C pneumoniae evaluated, 97.2% of those treated with macrolides and 81.7% treated with other antibiotics were considered cured or improved after 4 to 6 weeks (P < .05). In addition to highlighting improved outcomes with macrolides in children diagnosed with M pneumoniae and/or C pneumoniae infection, these data also reveal a high rate of clinical improvement in the absence of targeted therapy. Other studies have found moderate reductions in length of fever and hospital length of stay in children with M pneumoniae CAP who were prescribed macrolides [47, 48] .
CONCLUSIONS
Given recent evidence of the burden of respiratory viruses in children with CAP, increasing rates of macrolide resistance in both S pneumoniae and M pneumoniae, and the lack of clinical trial data that show a clear benefit over alternative agents, the role of macrolide antibiotics in children with CAP remains unclear. Yet, with M pneumoniae frequently detected (particularly in older children), observational data indicating modest improvements in outcomes with therapy, and data indicating the additional activity of macrolide antibiotics in patients with acute and chronic infective and inflammatory conditions, it is likely that specific patient groups can benefit from treatment with macrolide antibiotics. Defining this group and the role that macrolide antibiotics play is a research priority, particularly given the frequent prescription of macrolides [5, [49] [50] [51] and the development of newer macrolide antibiotics. Despite decades of use for acute respiratory tract infection, an adequately powered clinical trial is the only way to determine the benefits, risks, and costs (both economic and resistance) according to age group and in children with CAP attributable to specific pathogens. A number of challenges need to be considered when designing such trials in children, including defining optimal end points and standardizing diagnostic procedures, particularly for pathogens such as M pneumoniae. Given the self-limiting nature of viral pneumonia and M pneumoniae disease, it is likely that the time to symptom resolution or time to pathogen clearance is a more feasible end point than the more traditional pneumonia trial end points, including hospitalization and clinical failure [52] . Such trials need to be prioritized. 
